Get started
Author

Robert A. Ramirez

Management of Peptide Receptor Radionuclide Therapy Toxicities in Neuroendocrine Neoplasm Patients
2026 · Chirayu Mohindroo, Robert A. Ramirez · Current Treatment Options in Oncology · 3
PDF
Assessing Patient Characteristics in Neuroendocrine Tumor Research: A Comparison of the NET-PRO Study to SEER Population-Based Data
2026 · Michael A. O’Rorke, Bradley D. McDowell, et al. · Endocrine · 1
PDF
Abstract CT088: [212Pb]VMT-a-NET in advanced SSTR2+ neuroendocrine tumors: safety and preliminary efficacy results from dose-finding cohorts 1,2 and 3
2026 · Thorvardur R. Halfdanarson, Richard L. Wahl, et al. · Cancer Research · 1
Cohort-level safety and efficacy results for [ 212 Pb]VMT-α-NET in advanced somatostatin receptor subtype 2 (SSTR2+)–expressing neuroendocrine tumors (NETs): Cohorts 1–3.
2026 · Thorvardur Ragnar Halfdanarson, Richard L. Wahl, et al. · Journal of Clinical Oncology
Clinical practice review of systemic treatment in large cell neuroendocrine carcinoma
2026 · Amanda S. Cass, Isabella C. Luckage, et al. · Translational Lung Cancer Research
A phase 1 first-in-human, dose-escalation and -expansion study of RYZ401, a novel radiopharmaceutical therapy (RPT) labeled with actinium-225 ( 225 Ac), in patients with neuroendocrine tumors (NETs) and other solid tumors expressing somatostatin receptors (SSTRs).
2026 · Heloisa P. Soares, Rebecca K.S. Wong, et al. · Journal of Clinical Oncology
Using a participation monitoring database to enhance recruitment in a rare cancer population
2026 · Michael A. O’Rorke, Brian M. Gryzlak, et al. · Journal of Clinical and Translational Science
PDF
CO87 Treatment Patterns and Costs Associated with Small Cell Lung Cancer in a U.S. Medicare Population
2022 · P Cockrum, J MacEwan, et al. · Value in Health
Works count: 8
Citation count: 5
H-index: 1
I10-index:
Year
Topic
Type